期刊
CELL STEM CELL
卷 29, 期 2, 页码 189-208出版社
CELL PRESS
DOI: 10.1016/j.stem.2022.01.007
关键词
-
资金
- MEXT [JP20H00485, JP21H05273]
- Center Network for Realization Research Centers/Projects of Regenerative Medicine (the Program for Intractable Disease Research Utilizing Disease-specific iPS Cells and the Acceleration Program for Intractable Diseases Research Utilizing Disease-specific i [19bm0804003, 20bm0804003, 21bm0804003]
- Practical Research Project for Rare/Intractable Diseases from AMED [20ek0109492, 21ek0109492, 22ek0109492]
- Brain and Mind Research Promotion Program (Psychiatric/Neurological Disorder Mechanism Elucidation Project) from AMED [21wm042500900]
This review outlines the advances in iPSC modeling and therapeutic development for major neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and Alzheimer's disease.
It has been 15 years since the birth of human induced pluripotent stem cell (iPSC) technology in 2007, and the scope of its application has been expanding. In addition to the development of cell therapies using iPSC-derived cells, pathological analyses using disease-specific iPSCs and clinical trials to confirm the safety and efficacy of drugs developed using iPSCs are progressing. With the innovation of related technologies, iPSC applications are about to enter a new stage. This review outlines advances in iPSC modeling and ther-apeutic development for cardinal neurodegenerative diseases, such as amyotrophic lateral sclerosis, Parkin-son's disease, and Alzheimer's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
